Commence Bio
Biotechnology ResearchMaryland, United States2-10 Employees
The STaRT of something big in immunotherapy! Commence Bio is founded on the vision that cancer and inflammatory diseases can be optimally treated by rebooting patients’ immune systems with a new class of medicinal stem cells: MSC1 & MSC2. Through the use of proprietary Stimulated Toll-like Receptor Technology [STaRT], adult, allogeneic mesenchymal stem cells [MSC] are transformed into powerful immunomodulators that migrate to the sites of dysfunction and – via a multi-pronged effect - re-awaken appropriate immune responses. MSC1 & MSC2 have proven to be safe, potent, efficacious immunotherapies in pre-clinical models of disease, including ovarian cancer, demyelinating diseases (i.e. multiple sclerosis and Krabbe disease), acute lung injury/ARDS, Crohn’s disease, rheumatoid arthritis, and diabetic neuropathic pain. Commence Bio’s lead candidate is CMB-200, an MSC2 therapy for acute optic neuritis/clinically isolated syndrome, which is often the first sign of multiple sclerosis. About STaRT – Stimulated Toll-like Receptor Technology STaRT is inspired by nature, in that it utilizes mimetics for the body’s wound-healing signals to program mesenchymal stem cells [MSC] as either anti-tumor (MSC1) or anti-inflammatory (MSC2) phenotypes. Thus, beginning with the favorable safety profile of naïve MSCs and their appreciable anti-inflammatory properties, STaRT 32 involves stimulation of Toll-Like Receptor 3 [TLR3] within MSCs to create MSC2s - a uniform, more potent population of cells with enhanced immunomodulatory properties. Conversely, STaRT 41 involves stimulation of TLR4 to create MSC1s, a new cancer immunotherapy that safely re-awakens both innate and adaptive immune responses.
1-888-653-2347 
support@leadiq.com 
